Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 424031, 8 pages
http://dx.doi.org/10.1155/2015/424031
Review Article

Novel Anticoagulants in Atrial Fibrillation: Monitoring, Reversal and Perioperative Management

1Division of Cardiovascular Diseases, Mayo Clinic, Phoenix, AZ, USA
2Damascus University Faculty of Medicine, Damascus, Syria
3Division of Cardiovascular and Thoracic Anesthesiology, Mayo Clinic, Phoenix, AZ 85054, USA

Received 18 December 2014; Accepted 25 January 2015

Academic Editor: Michele Miragoli

Copyright © 2015 Fadi Shamoun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Colilla, A. Crow, W. Petkun, D. E. Singer, T. Simon, and X. Liu, “Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population,” The American Journal of Cardiology, vol. 112, no. 8, pp. 1142–1147, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. D. Lloyd-Jones, R. J. Adams, T. M. Brown et al., “Heart disease and stroke statistics—2010 update: a report from the American Heart Association,” Circulation, vol. 121, pp. e46–e215, 2010. View at Publisher · View at Google Scholar
  3. S. Penado, M. Cano, O. Acha, J. L. Hernández, and J. A. Riancho, “Atrial fibrillation as a risk factor for stroke recurrence,” The American Journal of Medicine, vol. 114, no. 3, pp. 206–210, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Pirmohamed, “Warfarin: almost 60 years old and still causing problems,” British Journal of Clinical Pharmacology, vol. 62, no. 5, pp. 509–511, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Neidecker, A. A. Patel, W. W. Nelson, and G. Reardon, “Use of warfarin in long-term care: a systematic review,” BMC Geriatrics, vol. 12, article 14, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Birman-Deych, M. J. Radford, D. S. Nilasena, and B. F. Gage, “Use and effectiveness of warfarin in medicare beneficiaries with atrial fibrillation,” Stroke, vol. 37, no. 4, pp. 1070–1074, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. E. M. Hylek, C. Evans-Molina, C. Shea, L. E. Henault, and S. Regan, “Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation,” Circulation, vol. 115, no. 21, pp. 2689–2696, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. D. S. Budnitz, M. C. Lovegrove, N. Shehab, and C. L. Richards, “Emergency hospitalizations for adverse drug events in older Americans,” The New England Journal of Medicine, vol. 365, no. 21, pp. 2002–2012, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. J. R. Chiong and R. J. Cheung, “Long-term anticoagulation in the extreme elderly with the newer antithrombotics: safe or sorry?” Korean Circulation Journal, vol. 43, no. 5, pp. 287–292, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Cumberworth, N. T. Mabvuure, M.-J. Hallam, and S. Hindocha, “Is home monitoring of international normalised ratio safer than clinic-based monitoring?” Interactive Cardiovascular and Thoracic Surgery, vol. 16, no. 2, pp. 198–201, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. D. A. Garcia and M. A. Crowther, “Reversal of warfarin: case-based practice recommendations,” Circulation, vol. 125, no. 23, pp. 2944–2947, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Mant, F. D. R. Hobbs, K. Fletcher et al., “Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial,” The Lancet, vol. 370, no. 9586, pp. 493–503, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Dogliotti, E. Paolasso, and R. P. Giugliano, “Novel oral anticoagulants in atrial fibrillation: a meta-analysis of large, randomized, controlled trials vs warfarin,” Clinical Cardiology, vol. 36, no. 2, pp. 61–67, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. Z. Harel, M. Sholzberg, P. S. Shah et al., “Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD,” Journal of the American Society of Nephrology, vol. 25, no. 3, pp. 431–442, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Sardar, S. Chatterjee, S. Chaudhari, and G. Y. H. Lip, “New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials,” Journal of the American Geriatrics Society, vol. 62, no. 5, pp. 857–864, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. G. A. Rosenberg, “Neurological diseases in relation to the blood-brain barrier,” Journal of Cerebral Blood Flow and Metabolism, vol. 32, no. 7, pp. 1139–1151, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. Boehringer Ingelheim Pharmaceuticals Inc, Highlights of Prescribing Information for Pradaxa (Dabigatran Etexilate) Capsules, Boehringer Ingelheim Pharmaceuticals Inc, 2014, http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf.
  18. J. W. Eikelboom, L. Wallentin, S. J. Connolly et al., “Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) Trial,” Circulation, vol. 123, no. 21, pp. 2363–2372, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. J. W. Eikelboom and J. I. Weitz, “Dabigatran monitoring made simple?” Thrombosis and Haemostasis, vol. 110, no. 3, pp. 393–395, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. G. J. Hankey and J. W. Eikelboom, “Dabigatran etexilate: a new oral thrombin inhibitor,” Circulation, vol. 123, no. 13, pp. 1436–1450, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Skeppholm, P. Hjemdahl, J. P. Antovic et al., “On the monitoring of dabigatran treatment in ‘real life’ patients with atrial fibrillation,” Thrombosis Research, vol. 134, no. 4, pp. 783–789, 2014. View at Publisher · View at Google Scholar
  22. G. Hapgood, J. Butler, E. Malan, S. Chunilal, and H. Tran, “The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the hemoclot thrombin inhibitor assay in patient plasma samples,” Thrombosis and Haemostasis, vol. 110, no. 2, pp. 308–315, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Fawole, H. A. Daw, and M. A. Crowther, “Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban,” Cleveland Clinic Journal of Medicine, vol. 80, no. 7, pp. 443–451, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Stangier, K. Rathgen, H. Sthle, and D. Mazur, “Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study,” Clinical Pharmacokinetics, vol. 49, no. 4, pp. 259–268, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. E. S. Eerenberg, P. W. Kamphuisen, M. K. Sijpkens, J. C. Meijers, H. R. Buller, and M. Levi, “Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects,” Circulation, vol. 124, no. 14, pp. 1573–1579, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. R. A. Bernstein, M. J. Alberts, and D. A. Garcia, “Letter by Bernstein et al regarding article, ‘reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects’,” Circulation, vol. 125, article e614, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Van Ryn, D. Ruehl, H. Priepke, N. Hauel, and W. Wienen, “Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate,” in Proceedings of the 13th Congess of the European Hematology Association, vol. 93, p. 148, June 2008, Abs.0370.
  28. F. Schiele, J. Van Ryn, K. Canada et al., “A specific antidote for dabigatran: functional and structural characterization,” Blood, vol. 121, no. 18, pp. 3554–3562, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Honickel, O. Grottke, J. Van Ryn, H. Ten Cate, R. Rossaint, and H. Spronk, “Use of a specific antidote to dabigatran (idarucizumab) reduces blood loss and mortality in dabigatran-induced and trauma-induced bleeding in pigs,” Critical Care, vol. 18, supplement 1, article P99, 2014. View at Publisher · View at Google Scholar
  30. J. Van Ryn, M. Schmoll, H. Pillu et al., “Effect of dabigatran on the ability to generate fibrin at a wound site and its reversal by idarucizumab, the antidote to dabigatran,” in Health Volunteers: an Exploratory Marker of Blood Loss, American Heart Association Scientific Sessions, Chicago, Illinois, USA, 2014, http://www.abstractsonline.com/pp8/#/3547/presentation/33249. View at Google Scholar
  31. B. Laulicht, S. Bakhru, C. Lee et al., “Abstract 11395: small molecule antidote for anticoagulants,” Circulation, vol. 126, Article ID A11395, 2012. View at Google Scholar
  32. K. A. A. Fox, J. P. Piccini, D. Wojdyla et al., “Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment,” European Heart Journal, vol. 32, no. 19, pp. 2387–2394, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. R. Rosenstein and D. Parra, “Rivaroxaban versus warfarin in nonvalvular atrial fibrillation,” The New England Journal of Medicine, vol. 365, no. 24, article 2334, 2011. View at Google Scholar · View at Scopus
  34. Janssen Pharmaceuticals: XARELTO (rivaroxaban) tablets, (prescribing information), 2015, http://www.xareltohcp.com/sites/default/files/pdf/xarelto_0.pdf.
  35. M. M. Samama, G. Contant, T. E. Spiro et al., “Laboratory assessment of rivaroxaban: a review,” Thrombosis Journal, vol. 11, article 11, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. G. Lu, F. R. Deguzman, S. J. Hollenbach et al., “A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa,” Nature Medicine, vol. 19, no. 4, pp. 446–451, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. M. A. Crowther, V. Mathur, M. Kitt et al., “A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for Fxa inhibitors,” Blood, vol. 122, article 3636, 2013. View at Google Scholar
  38. Portola Pharmaceuticals Inc, Andexanet Alfa: FXa Inhibitor Antidote, Portola Pharmaceuticals Inc, 2014, http://www.portola.com/clinical-development/andexanet-alfa-prt4445-fxa-inhibitor-antidote/.
  39. S. J. Connolly, J. Eikelboom, C. Joyner et al., “Apixaban in patients with atrial fibrillation,” The New England Journal of Medicine, vol. 364, pp. 806–817, 2011. View at Publisher · View at Google Scholar
  40. C. B. Granger, J. H. Alexander, J. J. McMurray et al., “Apixaban versus warfarin in patients with atrial fibrillation,” The New England Journal of Medicine, vol. 365, pp. 981–992, 2011. View at Publisher · View at Google Scholar
  41. J. Steffel and G. Hindricks, “Apixaban in renal insufficiency: successful navigation between the Scylla and Charybdis,” European Heart Journal, vol. 33, no. 22, pp. 2766–2768, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. S. H. Hohnloser, Z. Hijazi, L. Thomas et al., “Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial,” European Heart Journal, vol. 33, no. 22, pp. 2821–2830, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. R. C. Becker, H. Yang, Y. Barrett et al., “Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban—an oral, direct and selective factor Xa inhibitor,” Journal of Thrombosis and Thrombolysis, vol. 32, no. 2, pp. 183–187, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. M. A. Crowther, M. Kitt, T. Lorenz et al., “A phase 2 randomized double-blind, placebo-controlled trial of PRT4445, a novel, universal antidote for direct and indirect factor Xa inhibitors,” Journal of Thrombosis and Haemostasis, vol. 11, article 30, 2013. View at Google Scholar
  45. R. P. Giugliano, C. T. Ruff, E. Braunwald et al., “Edoxaban versus warfarin in patients with atrial fibrillation,” The New England Journal of Medicine, vol. 369, no. 22, pp. 2093–2104, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. J. I. Weitz, “Expanding use of new oral anticoagulants,” F1000Prime Reports, vol. 6, article 93, 2014. View at Publisher · View at Google Scholar
  47. J. E. Ansell, S. H. Bakhru, B. E. Laulicht et al., “Use of PER977 to reverse the anticoagulant effect of edoxaban,” The New England Journal of Medicine, vol. 371, no. 22, pp. 2141–2142, 2014. View at Publisher · View at Google Scholar
  48. Bristol-Myers Squibb, Highlights on Prescribing Information. ELIQUIS (Apixaban) Tablets for Oral Use, Bristol-Myers Squibb, 2012, http://packageinserts.bms.com/pi/pi_eliquis.pdf.